首页> 美国卫生研究院文献>SpringerPlus >A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study

【2h】

A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study

机译：S-1 /奥沙利铂联合贝伐单抗在晚期/转移性结直肠癌患者中的多机构可行性研究：HiSCO-02前瞻性II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeFOLFOX is a standard combination chemotherapy regimen for metastatic colorectal cancer (CRC). 5-Fluorouracil (5-FU) is infused continuously through a pump for 46 h; therefore, replacement of infused 5-FU with oral S-1 would be more convenient for patients. We investigated the efficacy and safety of S-1/oxaliplatin (SOX) plus bevacizumab regimen in a community setting.

机译：目的FOLFOX是用于转移性结直肠癌（CRC）的标准联合化疗方案。通过泵将5-氟尿嘧啶（5-FU）连续注入46小时;因此，用口服S-1代替输注的5-FU对患者将更方便。我们在社区中调查了S-1 /奥沙利铂（SOX）加上贝伐单抗方案的疗效和安全性。

著录项

期刊名称 SpringerPlus
作者
Manabu Shimomura; Katsunori Shinozaki; Takao Hinoi; Masanori Yoshimitsu; Manabu Kurayoshi; Daisuke Sumitani; Yasuyo Ishizaki; Takafumi Oshiro; Shinya Kodama; Yosuke Shimizu; Michinori Arita; Masakazu Tokunaga; Makoto Yoshida; Junko Tanaka; Hideki Ohdan;
展开▼
作者单位

展开▼
年(卷),期 -1(5),1
年度 -1
页码 1800
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
Metastatic colorectal cancer Chemotherapy S-1 Prospective phase II study;

机译：转移性结直肠癌;化学治疗;S-1;II期前瞻性研究;

相似文献

外文文献
中文文献
专利

1. 奥沙利铂和卡培他滨联合贝伐单抗加放疗的新辅助方案治疗局部晚期直肠癌:单中心Ⅱ期研究结果 [J] . Xin Yu, De-sen Wan, Pei-rong Ding, 癌症（英文版） . 2018,第008期
2. A Phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: A prospective, multicenter trial of the korean cancer study group [J] . HongY.S., LeeS.S., KimK.-P., American Journal of Clinical Oncology: Cancer Clinical Trials . 2014,第1期

机译：贝伐单抗，奥沙利铂和卡培他滨在先前未经治疗的转移性结直肠癌患者中的II期研究：一项韩国癌症研究组的前瞻性，多中心试验
3. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer [J] . Yoshito Komatsu, Chikashi Ishioka, Ken Shimada, BMC Cancer . 2015,第1期

机译：TRICOLORE试验的研究方案：以奥沙利铂为基础的化疗与联合用S-1，伊立替康和贝伐单抗联合化疗作为转移性结直肠癌一线治疗的III期随机研究
4. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (vol 21, pg 705, 2016) [J] . Miyamoto Yuji, Tsuji Akihito, Tanioka Hiroaki, International journal of clinical oncology . 2018,第2期

机译：S-1和Irinotecan Plus Bevacizumab作为奥沙利铂 - 难治转移性结直肠癌患者的二线化疗：日本的多中心期II研究（KSCC1102）（第21号，PG 705,2016）
5. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
6. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
7. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label non-inferiority randomised phase III: SOFT study [O] . Hideo Baba, Yasuhide Yamada, Daisuke Takahari, 2017

机译：S-1和奥沙利铂（SOX）加贝伐单抗与mFOLFOX6加贝伐单抗作为转移性结直肠癌患者的一线治疗：开放标签非自卑性随机III期的最新总体生存分析：SOFT研究
8. A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study [O] . 2016

机译：S-1 /奥沙利铂联合贝伐单抗在晚期/转移性结直肠癌患者中的多机构可行性研究：HiSCO-02前瞻性II期研究

A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅